Pharmaceuticals
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and ...
2022-02-23 23:00
2166
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is w...
2022-02-23 21:27
2274
SyMap Medical Ltd Completed Enrollment in SMART Study for the Treatment of Uncontrolled Hypertension
SUZHOU, China, Feb. 23, 2022 /PRNewswire/ -- SyMap Medical Ltd. (Suzhou, China) announced successful completion of enrollment in the company's SMART Study (S ympatheticMapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811), using the SyMapCath I™ Catheter/SYMPIONEER S1™ Ma...
2022-02-23 21:00
2281
Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced interim data from a Phase II clinical trial of STP705, a siRNA (small interfering RNA) therapeutic, ...
2022-02-23 17:53
2734
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group"; stock code: 2096.HK), announces a positive profit alert. Based on a preliminary assessment of the Group's unaudited consolidated management accounts for the ...
2022-02-23 16:22
3152
Radiaction Opens First EU Radiation Protection Center of Excellence in Collaboration with Mazowiecki Hospital in Ostrołęka, Poland
TEL AVIV, Israel, Feb. 22, 2022 /PRNewswire/ -- Radiaction Medical Ltd
2022-02-23 10:00
2098
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced that it has signed a Material Transfer Agreement (MTA) with one of the largest global pharmaceutical companies Eli Lilly and Company (hereinafter referred to as "Eli Lilly...
2022-02-22 20:52
3026
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
BEIJING, Feb. 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical trial of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of primary immune thrombocyto...
2022-02-22 17:09
2000
111 to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 17, 2022 - Conference Call to Follow
SHANGHAI, Feb. 22, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2022-02-22 16:38
1688
Nippon Express Obtains GDP Certification for Temperature-controlled Facility at Kansai International Airport
TOKYO, Feb. 22, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification, effectiveJanuary 11, for NX-PHARMA Logistics Hub Kansai Airport, a temperature-controlled fa...
2022-02-22 15:00
2404
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment ofAlmira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengt...
2022-02-21 22:00
2073
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development
* Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&D * Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, So...
2022-02-21 22:00
2102
Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced the publication of preclinical research of AN3025 (anti-hTNFR2）...
2022-02-21 21:00
1751
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-02-21 08:00
3154
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...
2022-02-18 22:10
6479
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China
NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor,...
2022-02-18 22:00
4103
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...
2022-02-18 08:19
1717
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...
2022-02-17 21:00
1586
Seegene Announces Q4 and Full-Year 2021 Financial Results
* Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY * Q4 Revenue of KRW 410 billion, up 34% QoQ * Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D * Seegene to make a strategic shift to a 'molecular diagnostics(MDx) plat...
2022-02-17 20:00
2400
Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL
SHANGHAI and NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, today announced that it has used its proprietary AI platform to nominate a preclinical candidate compound (PCC) for innova...
2022-02-17 16:30
2470
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10907
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
8349
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6812
